MDGL - Madrigal Pharmaceuticals, Inc.
| Previous Close | 287.00 |
| Open | 286.00 |
| Bid | 265.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's Range | 280.28 - 290.48 |
| 52 Week Range | 15.27 - 325.98 |
| Volume | 174,126 |
| Avg. Volume | 371,080 |
| Market Cap | 4.401B |
| Beta | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 321.17 |
- ACCESSWIRE•3 days ago
Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks
Stock Research Monitor: KTOV, LOXO, and MDGL LONDON, UK / ACCESSWIRE / July 17, 2018/ If you want a free Stock Review on MRTX sign up now at www.wallstequities.com/registration . Today, WallStEquities.com ...
Motley Fool•6 days agoThe 4 Best Biotech Stocks of 2018 (So Far)
Find out what's pushing shares of these biotechs through the roof.
- Motley Fool•9 days ago
3 Huge Biotech Winners in 2018 (So Far)
Why these stocks are the best biotech performers so far this year.
- ACCESSWIRE•17 days ago
Today's Research Reports on Trending Tickers: Madrigal Pharmaceuticals and Zuora
NEW YORK, NY / ACCESSWIRE / July 3, 2018 / U.S. equities closed up on Monday, supported by a rally from the technology sector. However, growing trade concerns continue to weigh on the markets. The Dow ...
- InvestorPlace•18 days ago
Best ETFs for 2018: ALPS Medical Breakthroughs ETF Keeps Rolling Along
This article is a part of InvestorPlace’s Best ETFs for 2018 contest. Todd Shriber’s pick for the contest is the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO). Albeit modestly, healthcare is one of the four sectors higher YTD, and biotechnology stocks are a big reason.
- Motley Fool•24 days ago
Viking Therapeutics, Buy the Dip?
Viking's shares finally pulled back last week. Should investors take advantage of this dip?
- Motley Fool•24 days ago
This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It
This NASH drug developer has a decent chance at beating all of its peers to market.
- Benzinga•27 days ago
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Evercore ISI's Josh Schimmer on June 19 upgraded bluebird from In-line to Outperform with a price target lifted from $175 to $230. Bluebird's recent updates related to its LentiGlobin investigational gene therapy in patients with sickle cell disease and the separate myeloma CAR-T therapy bb2121 with its partner Celgene Corporation (NASDAQ: CELG) represent an "important positive inflection" for the company, Schimmer said in the upgrade note.
- Motley Fool•last month
3 Top Biotech Stocks to Buy Right Now
These drug stocks are prescribing some serious growth potential in the years to come.
- Motley Fool•last month
Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
These two small biotechs with promising NASH drugs could attract several big suitors.
- Motley Fool•last month
Are These Red-Hot NASH Stocks Still a Buy?
Investors are piling into NASH stocks right now, but which ones are the best long-term buys?
- Bloomberg•last month
Madrigal Pharma Is Exploring Sale After Receiving Takeover Interest
Madrigal Pharmaceuticals Inc., with just nine employees and a market value of about $4.3 billion, is exploring a sale after receiving takeover interest from other drugmakers eyeing treatments for a liver disease linked to obesity, people familiar with the matter said. The deliberations are at an early stage and Madrigal may opt to continue operations on its own, they said. Representatives for Madrigal declined to comment, while Centerview didn’t immediately respond to calls.
- GlobeNewswire•last month
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
CONSHOHOCKEN, Pa., June 06, 2018-- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the ...
- GlobeNewswire•last month
Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
CONSHOHOCKEN, Pa., June 05, 2018-- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the ...
- ACCESSWIRE•2 months ago
Wired News - Madrigal Pharma Reported Encouraging Top-line Data at 36 Weeks from Phase-2 Clinical Trial of MGL-3196 in Patients with NASH
LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want access to our free research report on Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MDGL as the Company's latest news hit the wire. On May 31, 2018, the Company announced positive top-line, 36-week results from a Phase-2 clinical trial assessing MGL-3196, a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist, in patients with biopsy-proven non-alcoholic steatohepatitis (NASH). Active-Investors.com is currently working on the research report for Pulmatrix, Inc. (NASDAQ: PULM), which also belongs to the Healthcare sector as the Company Madrigal Pharma.
- MarketWatch•2 months ago
Madrigal Pharma shares skyrocket 145% on positive results for liver disease therapy
The mid-stage trial results sent the shares of many rivals in the NASH space downBloomberg NewsDMAMBMCMDMEMGZBZBRZDZDRZFZGZQZRZSZTZUMadrigal Pharmaceuticals Inc. shares soared as much as 145% in extremely heavy Thursday trade after the company released positive results for a phase 2 clinical trial for a type of liver disease called non-alcoholic steatohepatitis, or NASH.
- Benzinga•2 months ago
Maxim Explains Viking Therapeutics' Sympathy Move With Madrigal
Viking Therapeutics Inc (NASDAQ: VKTX ) shares more than doubled Thursday after a 145-percent jump in shares of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ), which announced data from a Phase 2 study of ...
- Motley Fool•2 months ago
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these three sizzling-hot biotech stocks keep the momentum going?
- Benzinga•2 months ago
Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 31) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) (Piper Jaffray initiated ...
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Madrigal Pharmaceuticals and Viking Therapeutics
NEW YORK, NY / ACCESSWIRE / June 1, 2018 / It was a day of gains for biotech stocks Madrigal Pharmaceuticals and Viking Therapeutics. Madrigal Pharmaceuticals released results of its phase II clinical ...
- Investopedia•2 months ago
Viking Therapeutics Breaks Out to Key Resistance Levels
Shares of the biopharmaceutical company soared on an improved outlook for its leading drug candidate.
- Motley Fool•2 months ago
Why Madrigal Pharmaceuticals, Brink's, and Applied Optoelectronics Jumped Today
Find out which of these stocks more than doubled.
- American City Business Journals•2 months ago
145% climb: Madrigal Pharmaceuticals' stock soars on positive study results
The West Conshohocken biopharmaceutical company is working on a drug to treat NASH, a common liver disease. Its experimental therapy is heading to late-stage testing.
Yahoo Finance Video•last monthMARKETS: Here's why stocks are dropping right now
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front.
